AIM VACCINE (06660) announced on August 24 that it has submitted a marketing registration application to the National Medical Products Administration for its self-developed next-generation high-potency human diploid cell rabies vaccine. This competitively positioned rabies vaccine is approaching registration and market launch, and will join the company's serum-free next-generation rabies vaccine and Vero cell rabies vaccine to form a comprehensive portfolio of advanced rabies vaccines, positioning the company to capture market share.

According to the results of the completed Phase III clinical trial unblinding, AIM VACCINE's next-generation high-potency human diploid cell rabies vaccine demonstrates favorable safety, immunogenicity, and immune persistence profiles. Its immunogenicity and immune persistence are superior to comparable control vaccines, with all endpoints fully meeting the pre-specified evaluation criteria of the clinical trial.

Wu Jinan, General Manager of AIM Honor, has publicly stated: "We are very confident in this human diploid cell rabies vaccine. It should be the rabies vaccine with the most advanced production process, the best potency and safety quality, and the most convenient injection method available domestically."

In the face of intense market competition, Wu believes new opportunities lie in immunization schedules, specifically in the number and frequency of doses. Currently, most rabies vaccine immunization schedules in the market are completed within three to four weeks, leaving significant room for optimization in vaccination approaches. AIM VACCINE's product supports both a simplified four-dose regimen and a 2-1-1 four-dose regimen, which enhances patient compliance. Based on this, its competitive strength and growth potential are worthy of anticipation.

Rabies is one of the world's most lethal diseases, with a fatality rate approaching nearly 100% once symptoms develop. Currently, there is no effective clinical treatment for rabies, making prevention a long-term necessity. As the world's second-largest supplier of rabies vaccines, AIM VACCINE is committed to leading deep technological iteration and upgrading in the global rabies vaccine sector, providing the market with a series of rabies vaccine products with better quality and higher safety, further solidifying the company's leading position in the global rabies vaccine field.

With the expected approval of the next-generation high-potency human diploid cell rabies vaccine, it will create synergies with the existing rabies vaccine series, strengthening the core competitiveness of the company's rabies vaccine products and consolidating its industry leadership. At the same time, as part of its globalization strategy, it can contribute additional revenue, reinforce AIM VACCINE's market position, and add new momentum to its sustained and stable growth.